United Kingdom Adrenocorticotropic Hormone Market Insight
United Kingdom Adrenocorticotropic Hormone Market is growing at an 7.16% CAGR, driven by rising endocrine disorders, NHS support, advanced hormone therapies, biologics, and improving diagnostic awareness nationwide.
United Kingdom Adrenocorticotropic Hormone Market Insights Forecasts to 2035
- The United Kingdom Adrenocorticotropic Hormone Market Size Was Estimated at USD 98.37 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 7.16% from 2025 to 2035
- The United Kingdom Adrenocorticotropic Hormone Market Size is Expected to Reach USD 196.5 Million by 2035
Notable Insights for United Kingdom Adrenocorticotropic Hormone Market
- By product type, repository corticotropin injections dominated, accounting for approximately 72% share in 2024, supported by their effectiveness in treating infantile spasms and autoimmune conditions.
- By application, treatment of infantile spasms dominated, holding approximately 57% share, driven by increasing early diagnosis and specialist pediatric neurology referrals across the UK.
- Approximately 0.04% of the UK population is affected by adrenal insufficiency and related endocrine disorders requiring ACTH diagnostic or therapeutic interventions.
Download the eBook (ToC)
- Around 74% of diagnosed patients receive hormone-based therapies through hospital-led endocrine care programs, while a smaller proportion undergo specialized biologic or adjunctive treatments.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Adrenocorticotropic Hormone Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Adrenocorticotropic Hormone Market
- Mallinckrodt Pharmaceuticals
- Pfizer
- Novartis
- Sanofi
- Eli Lilly and Company
- Ferring Pharmaceuticals
- AbbVie
- Merck KGaA
- Others
Recent Developments:
- In October 2024, Oxford-based OMass Therapeutics nominated an MC2 receptor clinical candidate targeting ACTH-related disorders, including congenital adrenal hyperplasia and Cushing’s syndrome, strengthening innovation in endocrine therapeutics.
- In June 2024, UCLH advanced clinical evaluation of CRN04894, an ACTH receptor antagonist for congenital adrenal hyperplasia, supporting innovative hormone-targeted therapies reducing steroid dependence in endocrine disorder management.
Market Segmentation:
United Kingdom Adrenocorticotropic Hormone Market, By Product Type
- Natural ACTH
- Synthetic ACTH
- Repository Corticotropin Injection
- Others
United Kingdom Adrenocorticotropic Hormone Market, By Application
- Infantile Spasms
- Multiple Sclerosis
- Nephrotic Syndrome
- Adrenal Insufficiency Diagnosis
- Others
United Kingdom Adrenocorticotropic Hormone Market, By End User
- Hospitals & Clinics
- Home Care Settings
- Specialty Endocrine Centers
- Research Institutes
United Kingdom Adrenocorticotropic Hormone Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The UK Adrenocorticotropic Hormone Market is expected to grow number of diagnoses of endocrine disorders, awareness regarding rare neurological disorders, and better access by the NHS to hormonal treatments. According to experts, there will be continued dominance for repository corticotropin treatments due to their efficacy in treating infantile spasms and autoimmune diseases. Biologic development, endocrinology, and personalization are the areas expected to drive the growth of the market until 2035.